|
1
|
Smyth E, Nilsson M, Grabsch H, van Grieken
N and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Connor A, O'Morain C and Ford A:
Population screening and treatment of Helicobacter pylori
infection. Nat Rev Gastroenterol Hepatol. 14:230–240. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schulz C, Schutte K, Mayerle J and
Malfertheiner P: The role of the gastric bacterial microbiome in
gastric cancer: Helicobacter pylori and beyond. Therap Adv
Gastroenterol. 12:17562848198940622019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zang Z, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sethi NS, Kikuchi O, Duronio GN, Stachler
MD, McFarland JM, Ferrer-Luna R, Zhang Y, Bao C, Bronson R, Patil
D, et al: Early TP53 alterations engage environmental exposures to
promote gastric premalignancy in an integrative mouse model. Nat
Genet. 52:219–230. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ebert M, Yu J, Hoffmann J, Rocco A, Röcken
C, Kahmann S, Müller O, Korc M, Sung JJ and Malfertheiner P: Loss
of beta-catenin expression in metastatic gastric cancer. J Clin
Oncol. 21:1708–1714. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zarkavelis G, Boussios S, Papadaki A,
Katsanos KH, Christodoulou DK and Pentheroudakis G: Current and
future biomarkers in colorectal cancer. Ann Gastroenterol.
30:613–621. 2017.PubMed/NCBI
|
|
9
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rupaimoole R, Calin G, Lopez-Berestein G
and Sood A: miRNA deregulation in cancer cells and the tumor
microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Wang S, Lai Q, Fang Y, Wu C, Liu
Y, Li Q, Wang X, Gu C, Chen J, et al: Cancer-associated
fibroblasts-derived exosomal miR-17-5p promotes colorectal cancer
aggressive phenotype by initiating a RUNX3/MYC/TGF-β1 positive
feedback loop. Cancer Lett. 491:22–35. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y
and Fan D: miR-17-5p promotes proliferation by targeting SOCS6 in
gastric cancer cells. FEBS Lett. 588:2055–2062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song J, Liu Y, Wang T, Li B and Zhang S:
miR-17-5p promotes cellular proliferation and invasiveness by
targeting RUNX3 in gastric cancer. Biomed Pharmacother.
128:1102462020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Y, Liu G, Li S and Liu X: miR-17-5p
knockdown inhibits proliferation, autophagy and promotes apoptosis
in thyroid cancer via targeting PTEN. Neoplasma. 67:249–258. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Jia X, Liu Y, Dong JH, Ren XM, Xu
O, Liu SH and Shan CG: Silencing of miR-17-5p suppresses cell
proliferation and promotes cell apoptosis by directly targeting
PIK3R1 in laryngeal squamous cell carcinoma. Cancer Cell Int.
20:142020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Xu W, Wang Y, Xu X, Lv S and Dong
X: miR-17-5p promotes migration and invasion in breast cancer cells
by repressing netrin 4. Int J Clin Exp Pathol. 12:1649–1657.
2019.PubMed/NCBI
|
|
17
|
Wang G, Zhou Y, Chen W, Yang Y, Ye J, Ou H
and Wu H: miR-21-5p promotes lung adenocarcinoma cell
proliferation, migration and invasion via targeting WWC2. Cancer
Biomark. 28:549–559. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiao T and Jie Z: MiR-21 promotes the
invasion and metastasis of gastric cancer cells by activating
epithelial-mesenchymal transition. Eur Surg Res. 60:208–218. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun L, Tian D, Yang Z and Li J: Exosomal
miR-21 promotes proliferation, invasion and therapy resistance of
colon adenocarcinoma cells through its target PDCD4. Sci Rep.
10:82712020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim K, Kim HH, Lee CH, Kim S, Cheon GJ,
Kang KW, Chung JK and Youn H: Therapeutic efficacy of modified
anti-miR21 in metastatic prostate cancer. Biochem Biophys Res
Commun. 529:707–713. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boussios S, Ozturk MA, Moschetta M,
Karathanasi A, Zakynthinakis-Kyriakou N, Katsanos KH, Christodoulou
DK and Pavlidis N: The developing story of predictive biomarkers in
colorectal cancer. J Pers Med. 9:122019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valenti MT, Deiana M, Cheri S, Dotta M,
Zamboni F, Gabbiani D, Schena F, Dalle Carbonare L and Mottes M:
Physical exercise modulates miR-21-5p, miR-129-5p, miR-378-5p, and
miR-188-5p expression in progenitor cells promoting osteogenesis.
Cells. 8:7422019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boussios S, Abson C, Moschetta M, Rassy E,
Karathanasi A, Bhat T, Ghumman F, Sheriff M and Pavlidis N: Poly
(ADP-Ribose) polymerase inhibitors: Talazoparib in ovarian cancer
and beyond. Drugs R D. 20:55–73. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pang W, Tian X, Bai F, Han R, Wang J, Shen
H, Zhang X, Liu Y, Yan X, Jiang F and Xing L: Pim-1 kinase is a
target of miR-486-5p and eukaryotic translation initiation factor
4E, and plays a critical role in lung cancer. Mol Cancer.
13:2402014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rask L, Balslev E, Søkilde R, Høgdall E,
Flyger H, Eriksen J and Litman T: Differential expression of
miR-139, miR-486 and miR-21 in breast cancer patients
sub-classified according to lymph node status. Cell Oncol (Dordr).
37:215–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma X, Wei J, Zhang L, Deng D, Liu L, Mei
X, He X and Tian J: miR-486-5p inhibits cell growth of papillary
thyroid carcinoma by targeting fibrillin-1. Biomed Pharmacother.
80:220–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang RA, Li ZS, Yan QG, Bian XW, Ding YQ,
Du X, Sun BC, Sun YT and Zhang XH: Resistance to apoptosis should
not be taken as a hallmark of cancer. Chin J Cancer. 33:47–50.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu H, Xu H, Lu F, Zhang J, Xu L, Xu S,
Jiang H, Zeng Q, Chen E and He Z: Exosome-derived miR-486-5p
regulates cell cycle, proliferation and metastasis in lung
adenocarcinoma via targeting NEK2. Front Bioeng Biotechnol.
8:2592020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saragoni L: Upgrading the definition of
early gastric cancer: Better staging means more appropriate
treatment. Cancer Biol Med. 12:355–361. 2015.PubMed/NCBI
|
|
31
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang MM, Lai MS, Hong SY, Pan BS, Huang
H, Yang SH, Wu CC, Sun HS, Chuang JI, Wang CY and Huang BM:
FGF9/FGFR2 increase cell proliferation by activating ERK1/2,
Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.
Cancer Sci. 109:3503–3518. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Tian X, Han R, Zhang X, Wang X,
Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of
miR-486-5p contributes to tumor progression and metastasis by
targeting protumorigenic ARHGAP5 in lung cancer. Oncogene.
33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang X, Zhang T, Yang K, Zhang M and Wang
K: miR-486-5p suppresses prostate cancer metastasis by targeting
Snail and regulating epithelial-mesenchymal transition. Onco
Targets Ther. 9:6909–6914. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shindo Y, Hazama S, Nakamura Y, Inoue Y,
Kanekiyo S, Suzuki N, Takenouchi H, Tsunedomi R, Nakajima M, Ueno
T, et al: miR-196b, miR-378a and miR-486 are predictive biomarkers
for the efficacy of vaccine treatment in colorectal cancer. Oncol
Lett. 14:1355–1362. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu X, Chen X, Zeng K, Xu M, He B, Pan Y,
Sun H, Pan B, Xu X, Xu T, et al: DNA-methylation-mediated silencing
of miR-486-5p promotes colorectal cancer proliferation and
migration through activation of PLAGL2/IGF2/β-catenin signal
pathways. Cell Death Dis. 9:10372018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shaham L, Vendramini E, Ge Y, Goren Y,
Birger Y, Tijssen MR, McNulty M, Geron I, Schwartzman O, Goldberg
L, et al: MicroRNA-486-5p is an erythroid oncomiR of the myeloid
leukemias of Down syndrome. Blood. 125:1292–1301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen H, Ren C, Han C, Wang D, Chen Y and
Fu D: Expression and prognostic value of miR-486-5p in patients
with gastric adenocarcinoma. PLoS One. 10:e01193842015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shao Y, Shen YQ, Li YL, Liang C, Zhang BJ,
Lu SD, He YY, Wang P, Sun QL, Jin YX and Ma ZL: Direct repression
of the oncogene CDK4 by the tumor suppressor miR-486-5p in
non-small cell lung cancer. Oncotarget. 7:34011–34021. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pisano A, Grinan-Lison C, Farace C,
Fiorito G, Fenu G, Jiménez G, Scognamillo F, Peña-Martin J,
Naccarati A, Pröll J, et al: The inhibitory role of miR-486-5p on
CSC phenotype has diagnostic and prognostic potential in colorectal
cancer. Cancers (Basel). 12:34322020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mattei MG, Penault-Llorca F, Coulier F and
Birnbaum D: The HumanFGF9Gene Maps to chromosomal region 13q11-q12.
Genomics. 29:811–812. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Giri D, Ropiquet F and Ittmann M: FGF9 is
an autocrine and paracrine prostatic growth factor expressed by
prostatic stromal cells. J Cell Physiol. 180:53–60. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hendrix N, Wu R, Kuick R, Schwartz D,
Fearon E and Cho K: Fibroblast growth factor 9 has oncogenic
activity and is a downstream target of Wnt signaling in ovarian
endometrioid adenocarcinomas. Cancer Res. 66:1354–1362. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen TM, Shih YH, Tseng JT, Lai MC, Wu CH,
Li YH, Tsai SJ and Sun HS: Overexpression of FGF9 in colon cancer
cells is mediated by hypoxia-induced translational activation.
Nucleic Acids Res. 42:2932–2944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu
YX, Liu JF and He ZM: miR-26a suppresses tumor growth and
metastasis by targeting FGF9 in gastric cancer. PLoS One.
8:e726622013. View Article : Google Scholar : PubMed/NCBI
|
